Remission — believe it or not. What’s happening in rheumatology this week? Dr. Jack Cush breaks down the latest news and journal reports on RheumNow: 10-year T2T data: 82% in remission Residual steroids don’t preserve remission Biologics linked to lower PsA risk GLP-1s + knee OA https://t.co/2Zf9g1Wehg

DERM on RheumNow PODCAST (September 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. https://t.co/QYX9G5UFg5

The GLP-1 Opportunity Cost in Rheumatology There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent. https://t.co/49EscdPOTG https://t.co/c0kSgOXZy7

Supervised Physiotherapy Wins after ACL Repair The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with https://t.co/8HWmkmIexr

The weight is off, the DMARDs are off - now what? Sometimes it’s only when we have effective solutions that we have to think about what to do next. And when that happens, remember why we do things in the first place. In an era when weight loss is happening on scale, now we need https://t.co/MTjU5YRS5q

Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. https://t.co/ZCDR8l2CsI https://t.co/PHgtgZu12G

Treatment for Obesity and Inflammation, but at what Cost? https://t.co/v87FxQqrAv https://t.co/Oonrexyp0F

Obesity & Biologic Treatment Response Prepared for "The Obesity Imperative" campaign. https://t.co/72TFW6BWgG https://t.co/XWFWoH2D33

Worldwide the Sjögren’s disease market size was valued at approximately $1 billion USD in 2025 and is projected to reach nearly $10 billion USD by 2036 (with annual growth of 26.2% during the forecast period from 2026 to 2036). https://t.co/kxwftpIDeo https://t.co/RnEbzqFi2W

QD Clinic: Managing Muscle and Fat Loss with GLP-1s Dr. David Liew, Melbourne, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign presented in September 2026. https://t.co/t9uD7TGKjZ https://t.co/BzE1m04E2s

ARthritis & CAncer (ARCA) is Spanish retro study of 728 #RA pts w/ Hx of CA & Rx w/ biologics. W/ F/U of 11 022 yrs, new/recurrent CA was not incr (7.3/1000PYs) & = Pts Rx w/ csDMARDs (HRs 0.94; 0.73,1.21) & not incr w/ TNFi (0.94), IL-6i (1.03), CD20i (0.81), JAKi (0.6), ABA https://t.co/UUWlsaYV0Z

Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of https://t.co/9GhEwXuCEI

Bringing TOGETHER-PsA Into Clinical Practice The TOGETHER-PsA trial provides prospective evidence supporting an integrated approach to PsA and weight management, reinforcing the importance of addressing both inflammatory disease activity and metabolic health as part of https://t.co/WmF4mdxDWR

GCA international survey of 155 specialists (rheums 51%; ophthal 33%). w/ GCA dx, ASA started in only 15%; w/ 69.5% uncertain. w/ visual loss, 93% Rheums, 85% Ophthal Rx w/ IVGC, followed by oral. Uncertainty for IV versus po GC seen in 68.5% https://t.co/sWZQv8yw3u https://t.co/08tdXxDve8